Alzheimer’s Drug Leqembi Gains FDA Panel’s Support for Full Approval

A radical of autarkic advisers to the U.S. Food and Drug Administration (FDA) person voted to enactment regulatory support of the Alzheimer’s drug Leqembi, besides known by its generic sanction lecanemab, contempt concerns surrounding 3 deaths during objective trials. The six members connected the Peripheral and Central Nervous System Drugs Advisory Committee connected Friday each voted successful favour of the FDA granting afloat support to Leqembi to dainty Alzhe...